Myocardial Infarction Research

Myocardial infarction (MI) - more commonly referred to as a heart attack - is an acute event caused by the interruption of blood supply to regions of the heart, leading to myocardial necrosis. Infarction of a substantial area of the myocardium can disrupt normal conductance of the heart, leading to cardiac arrest.In the majority of cases, an MI is immediately preceded by the presence of an occlusive thrombus within a coronary artery, blocking blood flow to the downstream tissue. The most common cause of an occlusive thrombus within a coronary artery is the rupture of an atherosclerotic plaque. However, the occlusion of a coronary artery may also result from coronary embolism. This can occur in patients following stent placement, angioplasty, and coronary artery bypass grafting.

Myocardial Infarction Research Products Targets

Products for Myocardial Infarction Research - Page 14

Cat.No. Product Name Information/Activity
BCC6199 Cardionogen 1 577696-37-8
BCC5581 CCG-1423 CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.
BCC3896 CH 223191 CH-223191 is a potent and specific antagonist of aryl hydrocarbon receptor (AhR). CH-223191 inhibits TCDD-mediated nuclear translocation and DNA binding of AhR, and inhibits TCDD-induced luciferase activity with an IC50 of 0.03 μM.
BCC5614 CKI 7 dihydrochloride 1177141-67-1
BCN2964 Cyclopamine Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay.
BCC3618 DAPT (GSI-IX) DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.
BCC1184 Dexamethasone (DHAP) Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18L expression on monocytes.
BCC8079 Dibutyryl-cAMP, sodium salt Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing.
BCC5329 DMH-1 DMH-1 is a potent and selective BMP inhibitor with IC50s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.
BCC4361 Dorsomorphin 2HCl Dorsomorphin dihydrochloride (Compound C dihydrochloride) is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride induces autophagy.